GlobalData predicts that Lilly’s retatrutide could reach sales of $15.6bn in 2031. Image credit: Jennie Book / Shutterstock.com. Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback